IPCALAB - Swing Trade Analysis with AI Signals

Last Updated Time : 05 Nov 25, 7:43 am

Swing Trade Rating: 3.6

💊 IPCALAB shows solid fundamentals but weak technical momentum. Entry near ₹1,270–₹1,285 is optimal. If already held, consider exiting near ₹1,340–₹1,360.

📈 Positive

• EPS ₹27.9 and P/E 36.1 — slightly above industry PE of 33.1
• ROCE 17.6% and ROE 12.6% — healthy capital efficiency
• Debt-to-equity 0.13 — low leverage
• DII holding increased by 0.57% — rising domestic investor confidence
• Quarterly PAT growth: ₹262 Cr. vs ₹134 Cr. — up 28.4%

⚠️ Limitation

• MACD -13.7 and RSI 46.7 — weak technical momentum
• Trading below DMA 50 (₹1,329) and DMA 200 (₹1,382) — bearish bias
• PEG ratio -49.5 — unreliable valuation metric
• Dividend yield 0.31% — minimal income support
• FII holding declined by 0.25%

🚫 Company Negative News

• Stock down ~26% from 52-week high of ₹1,758
• MACD and RSI suggest lack of momentum for immediate breakout

✅ Company Positive News

• Strong Q2 performance driven by API exports and branded formulations
• Positive sentiment around pharma sector recovery and margin expansion
• Analysts expect medium-term recovery toward ₹1,400+ levels

🏭 Industry

• Pharma sector benefits from global demand, regulatory approvals, and domestic healthcare expansion
• IPCALAB trades slightly above industry PE (33.1) — reflects premium for brand and export strength

🧾 Conclusion

• IPCALAB is a fundamentally strong but technically weak swing candidate
• Best entry: ₹1,270–₹1,285 near support and RSI base
• If already held, exit near ₹1,340–₹1,360 — resistance zone below DMA 50
• Watch for MACD crossover and RSI >50 for confirmation

I can also compare IPCALAB with other pharma stocks like SUNPHARMA or CIPLA to help you spot stronger swing setups.